Super p53 for Treatment of Ovarian Cancer
Abstract
In this report, we show preliminary data indicating that gene therapy using re-engineered super p53 (p53-CC constructs) is effective in killing ovarian cancer cells in vitro. This is unreported, novel finding paves the way for using super p53 for ovarian cancer treatment. Main activities and objectives completed to date include optimization of cell culture growth and determining transfection conditions for human ovarian cancer cell lines, including Kuramochi, OVCAR3, SKOV3, SKOV3.ip1, and mouse ovarian cancer cells (ID8). 7AAD and MTT assay conditions have been optimized. WSLP (polymer) has been successfully synthesized, and a subset of adenoviral constructs have been cloned (p53, p53-CC, EGFP control). Major results: Gene therapeutic super p53 (p53-CC) localizes mainly to the nucleus in human ovarian cancer cells (Kuramochi) and exclusively in mouse cells (ID8) as demonstrated by fluorescence microscopy. Preliminary studies indicate that p53-CC causes robust apoptosis in Kuramochi and ID8 cells as well, measured using the 7AAD assay (late stage apoptosis). IC50 values for taxol have been determined in ID8 (and SKOV3) cells. In ID8 cells (which will be used to implant into mice for the syngeneic animal study), p53-CCmut causes the highest levels of apoptosis regardless of whether taxol is added, as seen in vitro.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2016
- Accession Number
- AD1013642
Entities
People
- Carol S. Lim
Organizations
- University of Utah